Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 413076, 21 pages
http://dx.doi.org/10.1155/2015/413076
Review Article

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

1Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia
2Gynaeoncology Unit, Royal Women’s Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia
3Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia

Received 20 February 2015; Accepted 7 April 2015

Academic Editor: Rohit S. Mulik

Copyright © 2015 Nirmala Chandralega Kampan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre (Australia), Ovarian Cancer in Australia: An Overview, 2010, Cancer Series, Australian Institute of Health and Welfare, Canberra, Australia, 2010.
  2. R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1248–1259, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Kemp and J. A. Ledermann, “Update on first-line treatment of advanced ovarian carcinoma,” International Journal of Women's Health, vol. 5, no. 1, pp. 45–51, 2013. View at Google Scholar · View at Scopus
  4. A. du Bois, H.-J. Lück, W. Meier et al., “A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer,” Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1320–1330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. R. F. Ozols, B. N. Bundy, B. E. Greer et al., “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3194–3200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. W. P. McGuire, W. J. Hoskins, M. F. Brady et al., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer,” The New England Journal of Medicine, vol. 334, no. 1, pp. 1–6, 1996. View at Google Scholar
  7. W. P. McGuire, W. J. Hoskins, M. F. Brady et al., “Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the gynecologic oncology group),” Seminars in Oncology, vol. 23, no. 5, supplement 12, pp. 40–47, 1996. View at Google Scholar · View at Scopus
  8. M. J. Piccart, K. Bertelsen, K. James et al., “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 699–708, 2000. View at Google Scholar
  9. P. A. Vasey, G. C. Jayson, A. Gordon et al., “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherpy for ovarian carcinoma,” Journal of the National Cancer Institute, vol. 96, no. 22, pp. 1682–1691, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Gronlund, C. Hogdall, H. H. Hansen, and S. A. Engelholm, “Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer,” Gynecologic Oncology, vol. 83, no. 1, pp. 128–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. T. M. Loffler, W. Freund, J. Lipke, and T.-U. Hausamen, “Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial,” Seminars in Oncology, vol. 23, no. 6, supplement 16, pp. 32–34, 1996. View at Google Scholar · View at Scopus
  12. D. Fennelly, C. Aghajanian, F. Shapiro et al., “Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 187–192, 1997. View at Google Scholar · View at Scopus
  13. N. R. Abu-Rustum, C. Aghajanian, R. R. Barakat, D. Fennelly, F. Shapiro, and D. Spriggs, “Salvage weekly paclitaxel in recurrent ovarian cancer,” Seminars in Oncology, vol. 24, no. 5, supplement 15, pp. S15-62–S15-67, 1997. View at Google Scholar · View at Scopus
  14. M. Markman, B. N. Bundy, D. S. Alberts et al., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1001–1007, 2001. View at Google Scholar · View at Scopus
  15. A. Kikuchi, H. Sakamoto, and T. Yamamoto, “Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy,” International Journal of Gynecological Cancer, vol. 15, no. 1, pp. 45–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Cadron, K. Leunen, F. Amant, T. van Gorp, P. Neven, and I. Vergote, “The ‘Leuven’ dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer,” Gynecologic Oncology, vol. 106, no. 2, pp. 354–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Pignata, E. Breda, G. Scambia et al., “A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study,” Critical Reviews in Oncology/Hematology, vol. 66, no. 3, pp. 229–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Safra, S. Shamai, J. Greenberg et al., “Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma—a retrospective study,” Gynecologic Oncology, vol. 132, no. 1, pp. 18–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. L. J. Havrilesky, A. A. Alvarez, R. A. Sayer et al., “Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer,” Gynecologic Oncology, vol. 88, no. 1, pp. 51–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. van der Burg, W. Onstenk, I. Boere et al., “Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer,” European Journal of Cancer, vol. 50, no. 15, pp. 2592–2601, 2014. View at Google Scholar
  21. N. Katsumata, M. Yasuda, F. Takahashi et al., “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 374, no. 9698, pp. 1331–1338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Katsumata, M. Yasuda, S. Isonishi et al., “Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial,” The Lancet Oncology, vol. 14, no. 10, pp. 1020–1026, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Harano, F. Terauchi, N. Katsumata et al., “Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016),” Annals of Oncology, vol. 25, no. 1, pp. 251–257, 2014. View at Publisher · View at Google Scholar
  24. J. Chan, M. F. Brady, R. Penson et al., “Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/− bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712),” International Journal of Gynecological Cancer, vol. 23, no. 8, supplement 1, pp. 9–10, 2013. View at Google Scholar
  25. S. Pignata, G. Scambia, D. Katsaros et al., “Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial,” The Lancet Oncology, vol. 15, no. 4, pp. 396–405, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Walsh and J. Goodman, “From taxol to Taxol: the changing identities and ownership of an anti-cancer drug,” Medical Anthropology, vol. 21, no. 3-4, pp. 307–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Renneberg, “Biotech History: yew trees, paclitaxel synthesis and fungi,” Biotechnology Journal, vol. 2, no. 10, pp. 1207–1209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Liebmann, J. A. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. B. Mitchell, “Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines,” British Journal of Cancer, vol. 68, no. 6, pp. 1104–1109, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. Manfredi and S. B. Horwitz, “Taxol: an antimitotic agent with a new mechanism of action,” Pharmacology and Therapeutics, vol. 25, no. 1, pp. 83–125, 1984. View at Publisher · View at Google Scholar · View at Scopus
  30. D. G. I. Kingston, “Recent advances in the chemistry of taxol,” Journal of Natural Products, vol. 63, no. 5, pp. 726–734, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. D. G. I. Kingston, “The shape of things to come: structural and synthetic studies of taxol and related compounds,” Phytochemistry, vol. 68, no. 14, pp. 1844–1854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Walsh and J. Goodman, “Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug Taxol,” Social Science & Medicine, vol. 49, no. 9, pp. 1215–1225, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. P. H. Wiernik, E. L. Schwartz, J. J. Strauman, J. P. Dutcher, R. B. Lipton, and E. Paietta, “Phase I clinical and pharmacokinetic study of taxol,” Cancer Research, vol. 47, no. 9, pp. 2486–2493, 1987. View at Google Scholar · View at Scopus
  34. W. P. McGuire, E. K. Rowinsky, N. B. Rosenhein et al., “Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms,” Annals of Internal Medicine, vol. 111, no. 4, pp. 273–279, 1989. View at Publisher · View at Google Scholar · View at Scopus
  35. “Discovery and development of taxol,” in Taxol: Science and Applications, M. W. M. E. Suffness, Ed., pp. 3–25, CRC Press, Boca Raton, Fla, USA, 1995.
  36. M. J. Piccart and F. Cardoso, “Progress in systemic therapy for breast cancer: an overview and perspectives,” European Journal of Cancer, Supplement, vol. 1, no. 2, pp. 56–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Bonomi, K. B. Kim, and J. Kugler, “Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients with etoposide-cisplatin versus taxol-cisplatin: an Eastern Cooperative Oncology Group (ECOG) trial,” in Proceedings of the American Society of Clinical Oncology, vol. 16, p. 454a, 1997.
  38. D. Guénard, F. Guéritte-Voegelein, J. Dubois, and P. Potier, “Structure-activity relationships of Taxol and Taxotere analogues,” Journal of the National Cancer Institute. Monographs, no. 15, pp. 79–82, 1993. View at Google Scholar · View at Scopus
  39. D. G. I. Kingston, “Taxol: the chemistry and structure-activity relationships of a novel anticancer agent,” Trends in Biotechnology, vol. 12, no. 6, pp. 222–227, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. E. K. Rowinsky and R. C. Donehower, “Paclitaxel (taxol),” The New England Journal of Medicine, vol. 332, no. 15, pp. 1004–1014, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Parness and S. B. Horwitz, “Taxol binds to polymerized tubulin in vitro,” Journal of Cell Biology, vol. 91, no. 2, pp. 479–487, 1981. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Dammermann, A. Desai, and K. Oegema, “The minus end in sight,” Current Biology, vol. 13, no. 15, pp. R614–R624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Wiese and Y. Zheng, “Microtubule nucleation: γ-tubulin and beyond,” Journal of Cell Science, vol. 119, no. 20, pp. 4143–4153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Ganguly, H. Yang, and F. Cabral, “Paclitaxel-dependent cell lines reveal a novel drug activity,” Molecular Cancer Therapeutics, vol. 9, no. 11, pp. 2914–2923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. P. B. Schiff and S. B. Horwitz, “Taxol stabilizes microtubules in mouse fibroblast cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 3, pp. 1561–1565, 1980. View at Publisher · View at Google Scholar · View at Scopus
  46. P. B. Schiff, J. Fant, and S. B. Horwitz, “Promotion of microtubule assembly in vitro by Taxol,” Nature, vol. 277, no. 5698, pp. 665–667, 1979. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Zhang, R. Yang, S. Wang, and Z. Dong, “Paclitaxel: new uses for an old drug,” Drug Design, Development and Therapy, vol. 8, pp. 279–284, 2014. View at Google Scholar
  48. S. Rao, G. A. Orr, A. G. Chaudhary, D. G. I. Kingston, and S. B. Horwitz, “Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin,” The Journal of Biological Chemistry, vol. 270, no. 35, pp. 20235–20238, 1995. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Wang, Y. Cao, W. Zhao, H. Liu, Z. Fu, and R. Han, “Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression,” Journal of Pharmacological Sciences, vol. 93, no. 2, pp. 197–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Sevko, V. Kremer, C. Falk et al., “Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice,” Journal of Immunotoxicology, vol. 9, no. 3, pp. 275–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Kreis and R. Vale, Guidebook to the Cytoskeletal and Motor Proteins, Oxford University Press, Oxford, UK, 2nd edition, 1999.
  52. P. Giannakakou, D. L. Sackett, Y.-K. Kang et al., “Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization,” The Journal of Biological Chemistry, vol. 272, no. 27, pp. 17118–17125, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Rakovitch, W. Mellado, E. J. Hall, T. K. Pandita, S. Sawant, and C. R. Geard, “Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation,” International Journal of Radiation Oncology Biology Physics, vol. 44, no. 5, pp. 1119–1124, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. S. W. Lowe, S. Bodis, A. McClatchey et al., “p53 status and the efficacy of cancer therapy in vivo,” Science, vol. 266, no. 5186, pp. 807–810, 1994. View at Publisher · View at Google Scholar · View at Scopus
  55. C. C. Zhang, J.-M. Yang, E. White, M. Murphy, A. Levine, and W. N. Hait, “The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells,” Oncogene, vol. 16, no. 12, pp. 1617–1624, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Fukasawa, T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude, “Abnormal centrosome amplification in the absence of p53,” Science, vol. 271, no. 5256, pp. 1744–1747, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. T.-H. Wang, Y.-H. Chan, C.-W. Chen et al., “Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways,” Oncogene, vol. 25, no. 35, pp. 4857–4866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Yakirevich, E. Sabo, I. Naroditsky, Y. Sova, O. Lavie, and M. B. Resnick, “Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas,” Gynecologic Oncology, vol. 100, no. 1, pp. 152–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219–234, 2006. View at Publisher · View at Google Scholar
  60. L. W. Pfannenstiel, S. S. K. Lam, L. A. Emens, E. M. Jaffee, and T. D. Armstrong, “Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice,” Cellular Immunology, vol. 263, no. 1, pp. 79–87, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Klauber, S. Parangi, E. Flynn, E. Hamel, and R. J. D'Amato, “Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol,” Cancer Research, vol. 57, no. 1, pp. 81–86, 1997. View at Google Scholar · View at Scopus
  62. D. Belotti, V. Vergani, T. Drudis et al., “The microtubule-affecting drug paclitaxel has antiangiogenic activity,” Clinical Cancer Research, vol. 2, no. 11, pp. 1843–1849, 1996. View at Google Scholar · View at Scopus
  63. D. H. Lau, L. Xue, L. J. Young, P. A. Burke, and A. T. Cheung, “Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer,” Cancer Biotherapy and Radiopharmaceuticals, vol. 14, no. 1, pp. 31–36, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Jiang, “Harnessing the immune system for the treatment of breast cancer,” Journal of Zhejiang University: Science B, vol. 15, no. 1, pp. 1–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Gadducci, D. Katsaros, P. Zola et al., “Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: Results of an open noncomparative phase 2 multicenter italian study (after-6 protocol 2),” International Journal of Gynecological Cancer, vol. 19, no. 4, pp. 615–619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. R. S. Bhatt, J. Merchan, R. Parker et al., “A phase 2 pilot trial of low-dose, continuous infusion, or ‘metronomic’ paclitaxel and oral celecoxib in patients with metastatic melanoma,” Cancer, vol. 116, no. 7, pp. 1751–1756, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Caballero, J. J. Grau, J. L. Blanch et al., “Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) paclitaxel treatment for advanced head and neck cancer,” Archives of Otolaryngology—Head and Neck Surgery, vol. 133, no. 11, pp. 1143–1148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Alexandre, Y. Hu, W. Lu, H. Pelicano, and P. Huang, “Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species,” Cancer Research, vol. 67, no. 8, pp. 3512–3517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Hadzic, N. Aykin-Burns, Y. Zhu et al., “Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress,” Free Radical Biology and Medicine, vol. 48, no. 8, pp. 1024–1033, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. C. A. Sherman-Baust, K. G. Becker, W. H. Wood III, Y. Zhang, and P. J. Morin, “Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin,” Journal of Ovarian Research, vol. 4, no. 1, article 21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Agarwal and S. B. Kaye, “Ovarian cancer: strategies for overcoming resistance to chemotherapy,” Nature Reviews Cancer, vol. 3, no. 7, pp. 502–516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Acker and K. H. Plate, “Role of hypoxia in tumor angiogenesis—molecular and cellular angiogenic crosstalk,” Cell and Tissue Research, vol. 314, no. 1, pp. 145–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Höckel and P. Vaupel, “Biological consequences of tumor hypoxia,” Seminars in Oncology, vol. 28, supplement 8, no. 2, pp. 36–41, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Huang, Q.-H. Zhang, Q.-L. Ao, H. Xing, Y.-P. Lu, and D. Ma, “Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism,” Zhonghua Zhong Liu Za Zhi, vol. 29, no. 2, pp. 96–100, 2007. View at Google Scholar · View at Scopus
  75. N. Rohwer and T. Cramer, “Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways,” Drug Resistance Updates, vol. 14, no. 3, pp. 191–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. B. B. Aggarwal, R. V. Vijayalekshmi, and B. Sung, “Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe,” Clinical Cancer Research, vol. 15, no. 2, pp. 425–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. Z. Duan, R. Foster, D. A. Bell et al., “Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer,” Clinical Cancer Research, vol. 12, no. 17, pp. 5055–5063, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. H.-J. Kuh, S. H. Jang, M. G. Wientjes, J. R. Weaver, and J. L.-S. Au, “Determinants of paclitaxel penetration and accumulation in human solid tumor,” Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, pp. 871–880, 1999. View at Google Scholar · View at Scopus
  79. S. Arao, H. Suwa, M. Mandai et al., “Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways,” Cancer Research, vol. 54, no. 5, pp. 1355–1359, 1994. View at Google Scholar · View at Scopus
  80. S. E. Johnatty, J. Beesley, B. Gao et al., “ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas,” Gynecologic Oncology, vol. 131, no. 1, pp. 8–14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Yang, A. K. Iyer, A. Singh et al., “Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer,” Pharmaceutical Research, 2014. View at Publisher · View at Google Scholar
  82. D. A. Zajchowski, B. Y. Karlan, and L. K. Shawver, “Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas,” Molecular Cancer Therapeutics, vol. 11, no. 2, pp. 492–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. M. M. Gottesman, J. Ludwig, D. Xia, and G. Szakács, “Defeating drug resistance in cancer,” Discovery Medicine, vol. 6, no. 31, pp. 18–23, 2006. View at Google Scholar · View at Scopus
  84. S. Mozzetti, C. Ferlini, P. Concolino et al., “Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients,” Clinical Cancer Research, vol. 11, no. 1, pp. 298–305, 2005. View at Google Scholar · View at Scopus
  85. M. Kavallaris, D. Y. S. Kuo, C. A. Burkhart et al., “Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes,” Journal of Clinical Investigation, vol. 100, no. 5, pp. 1282–1293, 1997. View at Publisher · View at Google Scholar · View at Scopus
  86. G. A. Orr, P. Verdier-Pinard, H. McDaid, and S. B. Horwitz, “Mechanisms of Taxol resistance related to microtubules,” Oncogene, vol. 22, no. 47, pp. 7280–7295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Ferlini, L. Cicchillitti, G. Raspaglio et al., “Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77,” Cancer Research, vol. 69, no. 17, pp. 6906–6914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Mechetner, A. Kyshtoobayeva, S. Zonis et al., “Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin,” Clinical Cancer Research, vol. 4, no. 2, pp. 389–398, 1998. View at Google Scholar · View at Scopus
  89. J. S. Lagas, C. W. N. Damen, R. A. B. Van Waterschoot, D. Iusuf, J. H. Beijnen, and A. H. Schinkel, “P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine,” Molecular Pharmacology, vol. 82, no. 4, pp. 636–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. M. T. Huizing, J. B. Vermorken, H. Rosing et al., “Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial,” Annals of Oncology, vol. 6, no. 7, pp. 699–704, 1995. View at Google Scholar · View at Scopus
  91. R. Panchagnula, “Pharmaceutical aspects of paclitaxel,” International Journal of Pharmaceutics, vol. 172, no. 1-2, pp. 1–15, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. S. H. Jang, M. G. Wientjes, and J. L.-S. Au, “Determinants of paclitaxel uptake, accumulation and retention in solid tumors,” Investigational New Drugs, vol. 19, no. 2, pp. 113–123, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. D. S. Sonnichsen and M. V. Relling, “Clinical pharmacokinetics of paclitaxel,” Clinical Pharmacokinetics, vol. 27, no. 4, pp. 256–269, 1994. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Ohtsu, Y. Sasaki, T. Tamura et al., “Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion,” Clinical Cancer Research, vol. 1, no. 6, pp. 599–606, 1995. View at Google Scholar · View at Scopus
  95. M. Czejka, J. Schueller, H. Schnait, B. Springer, and I. Eder, “Clinical pharmacokinetics and metabolism of paclitaxel after a three-hour infusion: comparison of two preparations,” Journal of Oncology Pharmacy Practice, vol. 9, no. 4, pp. 129–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Rizzo, C. Riley, D. Von Hoff, J. Kuhn, J. Phillips, and T. Brown, “Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics,” Journal of Pharmaceutical and Biomedical Analysis, vol. 8, no. 2, pp. 159–164, 1990. View at Publisher · View at Google Scholar · View at Scopus
  97. V. A. de Weger, J. H. Beijnen, and J. H. M. Schellens, “Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel—a review,” Anti-Cancer Drugs, vol. 25, no. 5, pp. 488–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Kumar, H. Mahdi, C. Bryant, J. P. Shah, G. Garg, and A. Munkarah, “Clinical trials and progress with paclitaxel in ovarian cancer,” International Journal of Women's Health, vol. 2, no. 1, pp. 411–427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Huang, J. Zhao, J. C. Unkeless, Z. H. Feng, and H. Xiong, “TLR signaling by tumor and immune cells: a double-edged sword,” Oncogene, vol. 27, no. 2, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. R. A. Jibodh, J. S. Lagas, B. Nuijen, J. H. Beijnen, and J. H. M. Schellens, “Taxanes: old drugs, new oral formulations,” European Journal of Pharmacology, vol. 717, no. 1–3, pp. 40–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Javeed, M. Ashraf, A. Riaz, A. Ghafoor, S. Afzal, and M. M. Mukhtar, “Paclitaxel and immune system,” European Journal of Pharmaceutical Sciences, vol. 38, no. 4, pp. 283–290, 2009. View at Publisher · View at Google Scholar
  102. L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli, “Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer,” Cell Death and Differentiation, vol. 21, no. 1, pp. 15–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. C. A. Byrd-Leifer, E. F. Block, K. Takeda, S. Akira, and A. Ding, “The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol,” European Journal of Immunology, vol. 31, no. 8, pp. 2448–2457, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. A.-C. Wang, Y.-B. Ma, F.-X. Wu et al., “TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro,” Oncology Letters, vol. 7, no. 3, pp. 871–877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. Y. Zhu, N. Liu, S. D. Xiong, Y. J. Zheng, and Y. W. Chu, “CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4,” Scandinavian Journal of Immunology, vol. 73, no. 4, pp. 301–308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Kubo, T. Morisaki, K. Matsumoto et al., “Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production,” Cancer Immunology, Immunotherapy, vol. 54, no. 5, pp. 468–476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Markasz, G. Stuber, B. Vanherberghen et al., “Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells,” Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 644–654, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Sako, N. Burioka, K. Yasuda et al., “Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy,” Acta Oncologica, vol. 43, no. 1, pp. 15–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Kaneno, G. V. Shurin, I. L. Tourkova, and M. R. Shurin, “Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations,” Journal of Translational Medicine, vol. 7, article 58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. T. Michels, G. V. Shurin, H. Naiditch, A. Sevko, V. Umansky, and M. R. Shurin, “Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner,” Journal of Immunotoxicology, vol. 9, no. 3, pp. 292–300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. R. A. Kemp and F. Ronchese, “Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity,” The Journal of Immunology, vol. 167, no. 11, pp. 6497–6502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Y. Rudensky, “Regulatory T cells and Foxp3,” Immunological Reviews, vol. 241, no. 1, pp. 260–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. E. M. Shevach, “CD4+CD25+ suppressor T cells: more questions than answers,” Nature Reviews Immunology, vol. 2, no. 6, pp. 389–400, 2002. View at Google Scholar · View at Scopus
  114. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. H. Nishikawa and S. Sakaguchi, “Regulatory T cells in tumor immunity,” International Journal of Cancer, vol. 127, no. 4, pp. 759–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Fialová, S. Partlová, L. Sojka et al., “Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells,” International Journal of Cancer, vol. 132, no. 5, pp. 1070–1079, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. A. E. Albers, R. L. Ferris, G. G. Kim, K. Chikamatsu, A. B. DeLeo, and T. L. Whiteside, “Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites,” Cancer Immunology, Immunotherapy, vol. 54, no. 11, pp. 1072–1081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Liu, Y. Zheng, Y. Zhu, S. Xiong, and Y. Chu, “Selective impairment of CD4 + CD25 + Foxp3 + regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis,” International Immunopharmacology, vol. 11, no. 2, pp. 212–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. X. Wu, Q.-M. Feng, Y. Wang, J. Shi, H.-L. Ge, and W. Di, “The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy,” Cancer Immunology, Immunotherapy, vol. 59, no. 2, pp. 279–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. A. P. Vicari, R. Luu, N. Zhang et al., “Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse,” Cancer Immunology, Immunotherapy, vol. 58, no. 4, pp. 615–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. L. Zhang, K. Dermawan, M. Jin et al., “Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy,” Clinical Immunology, vol. 129, no. 2, pp. 219–229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. Y. Tabuchi, J. Matsuoka, M. Gunduz et al., “Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer,” International Journal of Oncology, vol. 34, no. 2, pp. 313–319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. N. Obermajer, R. Muthuswamy, K. Odunsi, R. P. Edwards, and P. Kalinski, “PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment,” Cancer Research, vol. 71, no. 24, pp. 7463–7470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. Q. M. Feng, W. Di, and X. Wu, “Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 25, no. 11, pp. 1023–1025, 2009. View at Google Scholar · View at Scopus
  126. A. D. Seidman, D. Hochhauser, M. Gollub et al., “Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 6, pp. 1877–1884, 1996. View at Google Scholar
  127. D. R. Spriggs, M. F. Brady, L. Vaccarello et al., “Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4466–4471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. G. A. Omura, M. F. Brady, K. Y. Look et al., “Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2843–2848, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. R. Simon and L. Norton, “The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens,” Nature Clinical Practice Oncology, vol. 3, no. 8, pp. 406–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Kumar, P. Hoskins, and A. Tinker, “Dose-dense paclitaxel in advanced ovarian cancer,” Clinical Oncology, vol. 27, no. 1, pp. 40–47, 2015. View at Publisher · View at Google Scholar
  131. P. Marchetti, S. Urien, G. A. Cappellini, G. Ronzino, and C. Ficorella, “Weekly administration of paclitaxel: theoretical and clinical basis,” Critical Reviews in Oncology/Hematology, vol. 44, supplement, pp. S3–S13, 2002. View at Publisher · View at Google Scholar
  132. P. Francis, E. Rowinsky, J. Schneider, T. Hakes, W. Hoskins, and M. Markman, “Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study,” Journal of Clinical Oncology, vol. 13, no. 12, pp. 2961–2967, 1995. View at Google Scholar · View at Scopus
  133. H. Thomas and P. Rosenberg, “Role of weekly paclitaxel in the treatment of advanced ovarian cancer,” Critical Reviews in Oncology/Hematology, vol. 44, supplement, pp. S43–S51, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Markman, J. Markman, K. Webster et al., “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3120–3125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. P. H. O'Donnell, M. Eileen Dolan, E. Gamazon et al., “Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants,” Pharmacogenetics and Genomics, vol. 20, no. 5, pp. 327–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. M. J. Millward, M. J. Boyer, M. Lehnert et al., “Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients,” Annals of Oncology, vol. 14, no. 3, pp. 449–454, 2003. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Markman, “Intraperitoneal therapy of ovarian cancer,” Oncologist, vol. 1, no. 1-2, pp. 18–21, 1996. View at Google Scholar · View at Scopus
  138. M. Markman and J. L. Walker, “Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 988–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Fujiwara, S. Nagao, E. Aotani, and K. Hasegawa, “Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer,” Expert Opinion on Pharmacotherapy, vol. 14, no. 13, pp. 1797–1806, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Markman, E. Rowinsky, T. Hakes et al., “Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study,” Journal of Clinical Oncology, vol. 10, no. 9, pp. 1485–1491, 1992. View at Google Scholar · View at Scopus
  141. M. Markman, M. F. Brady, N. M. Spirtos, P. Hanjani, and S. C. Rubin, “Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2620–2624, 1998. View at Google Scholar · View at Scopus
  142. P. B. Panici, I. Palaia, M. Graziano, F. Bellati, N. Manci, and R. Angioli, “Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study,” Oncology, vol. 78, no. 1, pp. 20–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” The New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  144. D. Tewari, J. Java, and R. Salani, “Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study,” in Proceedings of the 2013 Society of Gynecologic Oncology Annual Meeting on Women's Cancer, (GOG#114/172, Abstract), Los Angeles, Calif, USA, 2013.
  145. D. A. Yardley, “nab-paclitaxel mechanisms of action and delivery,” Journal of Controlled Release, vol. 170, no. 3, pp. 365–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Ando, K. Yonemori, N. Katsumata et al., “Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 2, pp. 457–465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. N. Desai, V. Trieu, Z. Yao et al., “Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel,” Clinical Cancer Research, vol. 12, no. 4, pp. 1317–1324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  148. J. A. Yared and K. H. R. Tkaczuk, “Update on taxane development: new analogs and new formulations,” Drug Design, Development and Therapy, vol. 6, pp. 371–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. M. G. Teneriello, P. C. Tseng, M. Crozier et al., “Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1426–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. R. L. Coleman, W. E. Brady, D. S. McMeekin et al., “A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 122, no. 1, pp. 111–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. J. W. Singer, “Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane,” Journal of Controlled Release, vol. 109, no. 1–3, pp. 120–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. C. Li, D.-F. Yu, R. A. Newman et al., “Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate,” Cancer Research, vol. 58, no. 11, pp. 2404–2409, 1998. View at Google Scholar · View at Scopus
  153. M. Mita, A. Mita, J. Sarantopoulos et al., “Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 2, pp. 287–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. P. Sabbatini, M. W. Sill, D. O'Malley, L. Adler, and A. A. Secord, “A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a gynecologic oncology group study,” Gynecologic Oncology, vol. 111, no. 3, pp. 455–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. M. O. Bradley, C. S. Swindell, F. H. Anthony et al., “Tumor targeting by conjugation of DHA to paclitaxel,” Journal of Controlled Release, vol. 74, no. 1–3, pp. 233–236, 2001. View at Publisher · View at Google Scholar · View at Scopus
  156. M. O. Bradley, N. L. Webb, F. H. Anthony et al., “Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel,” Clinical Cancer Research, vol. 7, no. 10, pp. 3229–3238, 2001. View at Google Scholar · View at Scopus
  157. A. C. Wolff, R. C. Donehower, M. K. Carducci et al., “Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile,” Clinical Cancer Research, vol. 9, no. 10, part 1, pp. 3589–3597, 2003. View at Google Scholar · View at Scopus
  158. A. Sparreboom, A. C. Wolff, J. Verweij et al., “Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies,” Clinical Cancer Research, vol. 9, no. 1, pp. 151–159, 2003. View at Google Scholar · View at Scopus
  159. P. M. Fracasso, J. Picus, J. D. Wildi et al., “Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 3, pp. 451–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Y. Bedikian, R. C. DeConti, R. Conry et al., “Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma,” Annals of Oncology, vol. 22, no. 4, pp. 787–793, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. Y.-N. Wu, S.-L. Wang, Y.-C. Wang et al., “Reversal effect of docosahexaenoic acid on taxol resistance in human ovarian carcinoma A2780/T cells,” Obstetrics & Gynecology International Journal, vol. 1, no. 3, Article ID 00018, 2014. View at Publisher · View at Google Scholar